SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Alkermes Launches Phase 2 Study of ALKS 7290

Alkermes has started a Phase 2 study of ALKS 7290 as adjunctive therapy to antidepressants in patients with major depressive disorder.

ALKS

Related stories